FDA pushes for broader powers to curb misleading direct to consumer drug advertising

Building on the Trump administration’s efforts to crack down on deceptive direct-to-consumer (DTC) prescription drug advertising, the Food and Drug Administration (FDA) has recently requested new authority from Congress to more strictly regulate DTC drug advertisements. As detailed in the FDA’s fiscal 2027 budget request, the proposal would amend Section 502 of the Federal Food, Drug, and Cosmetic Act to provide the agency greater authority to address misleading advertising that adversely... By: Herbert Smith Freehills Kramer